Candel Therapeutics (CADL) Total Current Liabilities (2020 - 2025)
Candel Therapeutics recorded quarterly Total Current Liabilities of $9.0 million in Q4 2025, down 17.68% quarter-over-quarter from $10.9 million in Q3 2025, and down 76.03% year-over-year from $37.5 million in Q4 2024.
Candel Therapeutics' Total Current Liabilities history runs 6 years deep, the most recent figure standing at $9.0 million for Q4 2025.
- In Q4 2025, Total Current Liabilities fell 76.03% year-over-year to $9.0 million; the TTM figure through Dec 2025 stood at $9.0 million (down 76.03% YoY), while the FY2025 annual figure was $9.0 million, down 76.03% from the prior year.
- Total Current Liabilities came in at $9.0 million for Q4 2025 at Candel Therapeutics, down from $10.9 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $37.5 million in Q4 2024 to a low of $4.4 million in Q3 2021.
- A 5-year average of $11.1 million and a median of $9.0 million in 2025 frame the typical range for Total Current Liabilities.
- Across the five-year window, Total Current Liabilities jumped 164.59% in 2024 and sank 76.03% in 2025, its largest moves.
- Candel Therapeutics' Total Current Liabilities stood at $5.4 million in 2021, then increased by 4.72% to $5.6 million in 2022, then surged by 152.61% to $14.2 million in 2023, then soared by 164.59% to $37.5 million in 2024, then tumbled by 76.03% to $9.0 million in 2025.
- According to Business Quant data, Total Current Liabilities over the past three periods registered $9.0 million, $10.9 million, and $14.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 16.35 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 1.70 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 636.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 66.94 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 13.42 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 3.88 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 5.11 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.35 Bn |
| 10 | Candel Therapeutics | 449.62 Mn | 449.62 Mn | - | 9.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 9.00 Mn |
| Sep 30, 2025 | 10.93 Mn |
| Jun 30, 2025 | 14.72 Mn |
| Mar 31, 2025 | 20.07 Mn |
| Dec 31, 2024 | 37.53 Mn |
| Sep 30, 2024 | 15.27 Mn |
| Jun 30, 2024 | 14.00 Mn |
| Mar 31, 2024 | 13.54 Mn |
| Dec 31, 2023 | 14.18 Mn |
| Sep 30, 2023 | 10.33 Mn |
| Jun 30, 2023 | 8.16 Mn |
| Mar 31, 2023 | 5.24 Mn |
| Dec 31, 2022 | 5.62 Mn |
| Sep 30, 2022 | 5.90 Mn |
| Jun 30, 2022 | 5.88 Mn |
| Mar 31, 2022 | 5.47 Mn |
| Dec 31, 2021 | 5.36 Mn |
| Sep 30, 2021 | 4.40 Mn |
| Jun 30, 2021 | 4.49 Mn |
| Dec 31, 2020 | 4.71 Mn |